AxoGen (AXGN) Competitors $18.00 -0.50 (-2.70%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$15.76 -2.24 (-12.47%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AXGN vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDREShould you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. AxoGen vs. Warby Parker LivaNova Enovis NovoCure TransMedics Group LeMaitre Vascular Tandem Diabetes Care Soleno Therapeutics CONMED Cadre Warby Parker (NYSE:WRBY) and AxoGen (NASDAQ:AXGN) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings. Does the media favor WRBY or AXGN? In the previous week, Warby Parker had 5 more articles in the media than AxoGen. MarketBeat recorded 9 mentions for Warby Parker and 4 mentions for AxoGen. AxoGen's average media sentiment score of 0.61 beat Warby Parker's score of 0.49 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, WRBY or AXGN? Warby Parker has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Which has stronger earnings & valuation, WRBY or AXGN? AxoGen has lower revenue, but higher earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWarby Parker$669.77M3.65-$63.20M-$0.27-89.00AxoGen$159.01M4.98-$21.72M-$0.32-56.25 Is WRBY or AXGN more profitable? Warby Parker has a net margin of -4.39% compared to AxoGen's net margin of -7.91%. Warby Parker's return on equity of -8.26% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets Warby Parker-4.39% -8.26% -4.37% AxoGen -7.91%-14.91%-7.49% Do institutionals and insiders believe in WRBY or AXGN? 93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 26.6% of Warby Parker shares are owned by insiders. Comparatively, 7.0% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in WRBY or AXGN? AxoGen received 414 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 72.76% of users gave AxoGen an outperform vote while only 42.11% of users gave Warby Parker an outperform vote. CompanyUnderperformOutperformWarby ParkerOutperform Votes4042.11% Underperform Votes5557.89% AxoGenOutperform Votes45472.76% Underperform Votes17027.24% Do analysts recommend WRBY or AXGN? Warby Parker presently has a consensus target price of $21.92, indicating a potential downside of 8.76%. AxoGen has a consensus target price of $18.33, indicating a potential upside of 1.85%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Warby Parker 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50AxoGen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryWarby Parker beats AxoGen on 10 of the 18 factors compared between the two stocks. Get AxoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXGN vs. The Competition Export to ExcelMetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$814.15M$3.41B$5.82B$9.13BDividend YieldN/A1.64%4.75%3.86%P/E Ratio-56.2516.9226.8119.21Price / Sales4.9873.23429.0769.52Price / CashN/A44.0938.0134.83Price / Book8.113.857.644.62Net Income-$21.72M$92.00M$3.19B$246.06M7 Day Performance-0.72%4.49%-2.13%-2.63%1 Month Performance-3.74%8.30%-1.11%-2.57%1 Year Performance73.58%14.29%15.71%12.71% AxoGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXGNAxoGen1.048 of 5 stars$18.00-2.7%$18.33+1.9%+76.0%$814.15M$159.01M-56.25450Upcoming EarningsNews CoverageWRBYWarby Parker2.5369 of 5 stars$25.70-2.7%$21.77-15.3%+69.9%$2.61B$669.77M-95.193,491Upcoming EarningsAnalyst ForecastLIVNLivaNova3.7044 of 5 stars$47.68+0.1%$69.17+45.1%-15.6%$2.59B$1.15B113.522,900Upcoming EarningsENOVEnovis3.4525 of 5 stars$43.89+0.4%$64.83+47.7%-33.0%$2.50B$1.71B-20.046,550Short Interest ↓Positive NewsNVCRNovoCure3.4767 of 5 stars$22.48+3.5%$32.67+45.3%+44.9%$2.43B$509.34M-16.061,453Upcoming EarningsNews CoverageTMDXTransMedics Group3.6176 of 5 stars$72.18+1.3%$122.70+70.0%-15.2%$2.42B$241.62M76.79210News CoverageGap UpLMATLeMaitre Vascular2.0323 of 5 stars$98.65+1.7%$94.63-4.1%+64.2%$2.22B$193.48M53.91490Positive NewsTNDMTandem Diabetes Care4.0733 of 5 stars$33.47+2.6%$53.81+60.8%+24.0%$2.20B$747.72M-17.342,400Upcoming EarningsPositive NewsSLNOSoleno Therapeutics4.5359 of 5 stars$49.17-4.2%$71.20+44.8%-5.1%$2.12BN/A-14.8130News CoveragePositive NewsCNMDCONMED4.6526 of 5 stars$63.05-2.1%$77.20+22.4%-25.0%$1.95B$1.31B14.874,000CDRECadre2.8965 of 5 stars$35.14-1.6%$39.67+12.9%-6.1%$1.43B$482.53M42.342,435 Related Companies and Tools Related Companies WRBY Alternatives LIVN Alternatives ENOV Alternatives NVCR Alternatives TMDX Alternatives LMAT Alternatives TNDM Alternatives SLNO Alternatives CNMD Alternatives CDRE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXGN) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.